Golpimec (Fingolimod)

Golpimec is prescribed for patients with relapsing forms of multiple sclerosis to help reduce the frequency of clinical relapses and slow disease progression.

• Reduces annualized relapse rate in adults with relapsing‑remitting MS.
• Delays accumulation of disability over time.
• May be considered as a first‑line disease‑modifying therapy.
• Used when oral administration is preferred over injectable options.
• Often selected for patients with active inflammatory disease activity.

Side effects of Golpimec vary in frequency and severity. Common reactions are usually mild to moderate, while serious events require immediate medical attention.

Common

• Headache
• Diarrhea or abdominal pain
• Upper respiratory tract infection
• Elevated liver enzymes
• Fatigue

Serious

• Severe infections (e.g., herpes zoster)
• Cardiac conduction abnormalities (e.g., bradycardia)
• Macular edema affecting vision
• Pulmonary function decline
• Elevated blood pressure or hypertension

Before starting Golpimec, clinicians assess several health factors to minimize risks. Patients should be monitored regularly throughout therapy.

• Contraindicated in pregnancy (Category X) and during breastfeeding.
• Baseline cardiac evaluation is required due to potential bradycardia.
• Liver function tests should be performed before and during treatment.
• Monitor for signs of infection; avoid live vaccines.
• Assess visual acuity for macular edema.
• Evaluate pulmonary status in patients with asthma or COPD.

Golpimec can interact with other medicines, affecting its safety profile or efficacy. Some combinations should be avoided, while others need careful monitoring.

Avoid

• Live or attenuated vaccines, because immune response is suppressed.
• Strong CYP4F2 inhibitors that may increase fingolimod exposure.

Use with caution

• Antihypertensive agents, as blood pressure may rise.
• Other immunosuppressants, which can heighten infection risk.
• Drugs that prolong QT interval, potentially affecting cardiac rhythm.